Company profile

ABBOTT LABORATORIES

NYSE:ABTBiotechnology: Pharmaceutical Preparations

Drug pipeline (85)

AssetStageRevenueTrialsStatus
ABT-072phase18no active trials
ABT-102phase11no active trials
ABT-384phase13no active trials
ABT-436phase13completed, terminated
ABT-510phase22completed, terminated

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (320)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01176201phase1completed2010-07-012010-10-01Abbott Products14-C ADME (Absorption, Disposition, Metabolism and Excretion) Study in Man
NCT01674712phase3completed2012-06-012013-10-01AbbottA 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
NCT00195793phase3completed2004-08-01AbbottA 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
NCT00743470phase1terminated2008-08-012008-10-01AbbottA Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
NCT00513370phase3completed2007-09-012008-09-01AbbottA Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis

FDA applications (117)

ApplicationTypeApplicantProducts
ANDA 061802ANDAABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
ANDA 062305ANDAROSS LABORATORIES DIV ABBOTT LABORATORIES INC
ANDA 062306ANDAROSS LABORATORIES DIV ABBOTT LABORATORIES INC
ANDA 062413ANDAABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV
ANDA 062547ANDAABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS DIV